Skip to main
NUVB
NUVB logo

Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio (NUVB) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvation Bio Inc. is strategically positioned in the oncology sector with its innovative therapeutic candidates, including taletrectinib, which targets a significant patient population suffering from ROS1+ non-small cell lung cancer (NSCLC). The company's clinical pipeline features multiple distinct product candidates, such as Safusidenib, NUV-1511, and NUV-868, indicating a commitment to addressing unmet medical needs in oncology. Additionally, the potential for revenue growth is bolstered by the substantial opportunity in the front-line ROS1+ NSCLC market, particularly as Nuvation Bio is currently the only developer pursuing treatment options in this area, leaving significant market share unaddressed by competitors.

Bears say

Nuvation Bio Inc faces several significant risks that contribute to a negative outlook for its stock. Key among these are the potential for negative clinical proof-of-concept data for its drug candidates, which could undermine investor confidence and hamper product development. Additionally, the expected commercial uptake of taletrectinib may fall short, driven by heightened competition and other market dynamics, while concerns about long-term dilution risk could further impact the company's financial stability and attractiveness to investors.

Nuvation Bio (NUVB) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvation Bio (NUVB) Forecast

Analysts have given Nuvation Bio (NUVB) a Buy based on their latest research and market trends.

According to 6 analysts, Nuvation Bio (NUVB) has a Buy consensus rating as of Oct 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvation Bio (NUVB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.